Overview

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sizhen Wang
Collaborator:
Shanghai Biomed-union Biotechnology Co., Ltd.